More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

Patients with metabolic dysfunction–associated steatohepatitis (MASH) saw reductions in liver fibrosis and steatohepatitis after 72 weeks of treatment with semaglutide (Ozempic, Wegovy; Novo ...

The diabetes and weight loss drug semaglutide may also reverse signs of liver disease. That’s the headline result of a new clinical trial that tested the popular medication in patients with MASH ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH). The interim results also reveal ...

How Can Wegovy Help? How does Wegovy (or any form of 2.4 mg dose of semaglutide) help with MASH?That's exactly what this trial set to find out. Researchers conducted a randomized, double-blind ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...

diabetes medication, fatty liver disease, fibrosis, inflammation, liver health, MASH, metabolic health, Ozempic, semaglutide, weight loss More in Health IQ 5 alarming flu signs that spell danger ...

In 154 adults with biopsy-diagnosed MASH, improvement without worsening fibrosis occurred in 53% of people treated with dapagliflozin (Farxiga) versus 30% on placebo (risk ratio [RR] 1.73, 95% CI ...